Opinion

Video

Patient Profile 3: A 67-Year-Old Male with Recurrent Prostate Cancer

Author(s):

Brian Helfand, MD, PhD,Brian Chapin, MD

Drs Helfand, Chapin, and Collins, review the case of 67-year-old man treated with recurring prostate cancer.

Current Time 0:00
Duration 9:24
Loaded: 1.75%
Stream Type LIVE
Remaining Time 9:24
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected
    • en (Main), selected
    Related Videos
    Female doctor typing on her laptop computer in medical office | Image Credit: © Rostislav Sedlacek - stock.adobe.com
    Study findings highlight gender gaps in oncology authorship and citation
    Jason Scovell, MD, on clinical utility of IsoPSA across racial groups
    Jason Scovell, MD, on clinical utility of IsoPSA across racial groups
    Jim Hu, MD, on urinary continence recovery across RARP techniques
    Jim Hu, MD, on urinary continence recovery across RARP techniques
    1 expert in this video
    Interpreting PSA Trends in Patients Receiving Darolutamide Plus ADT With mHSPC
    1 expert in this video
    Ultra-Low PSA Threshold vs Traditional Thresholds In Clinical Practice
    Michael S. Cookson, MD, FACS, and Kelly L. Stratton, MD, FACS, answer a question during a Zoom video interview
    Special Report: Tips for PCPs on evaluating prostate cancer risk
    Michael S. Cookson, MD, FACS, and Kelly L. Stratton, MD, FACS, answer a question during a Zoom video interview
    Special Report: Tailoring prostate cancer care for older adults
    Michael S. Cookson, MD, FACS, and Kelly L. Stratton, MD, FACS, answer a question during a Zoom video interview
    Special Report: New strategies emerge for metastatic prostate cancer
    Michael S. Cookson, MD, FACS, and Kelly L. Stratton, MD, FACS, answer a question during a Zoom video interview
    Special Report: Biden’s prostate cancer diagnosis renews focus on screening guidelines
    De novo metastatic prostate cancer: Understanding Biden’s prognosis and treatment options
    De novo metastatic prostate cancer: Understanding Biden’s prognosis and treatment options
    Related Content
    Conceptual image for prostate cancer treatment | Image Credit: © Dr_Microbe - stock.adobe.com
    May 30th 2025

    PEACE-3 data for radium-223/enzalutamide published in Annals of Oncology

    Benjamin P. Saylor
    The addition of Ra223 to enzalutamide was associated with a 31% reduction in the risk of progression or death compared with enzalutamide alone.
    Pearls & Perspectives: Helen Bernie, DO, MPH, at AUA 2025 | Credit: Urology Times
    April 27th 2025

    Pearls & Perspectives: Helen Bernie, DO, MPH, at AUA 2025

    Amy M. Pearlman, MD Helen L. Bernie, DO, MPH
    Helen Bernie, DO, MPH, joins the show to discuss data from her Indiana University team from the floor at AUA 2025.
    ORIC-944 shows promise in combination with AR inhibitors in mCRPC
    May 30th 2025

    ORIC-944 shows promise in combination with AR inhibitors in mCRPC

    Hannah Clarke
    Overall, 59% of patients achieved at least a 50% decline in PSA level.
    Dr. Murphy on increasing diversity in cancer clinical trials
    February 29th 2024

    Dr. Murphy on increasing diversity in cancer clinical trials

    Urology Times staff
    In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.
    Combination therapy linked to longer OS vs ADT in veterans with mHSPC
    May 27th 2025

    Combination therapy linked to longer OS vs ADT in veterans with mHSPC

    Hannah Clarke
    However, the data did not show any benefit of a docetaxel doublet vs an ARPI doublet.
    FDA Advisory Committee unanimously votes against talazoparib plus enzalutamide for mCRPC
    May 21st 2025

    FDA Advisory Committee unanimously votes against talazoparib plus enzalutamide for mCRPC

    Hannah Clarke
    The application is seeking an expanded indication of talazoparib plus enzalutamide for mCRPC.
    © 2025 MJH Life Sciences

    All rights reserved.